Sistema de Salut de Catalunya
Vivancos Prellezo, Ana
Benavides, Manuel
Elez Fernandez, Mª Elena
Gómez-España, Maria Auxiliadora
Toledano, Marta
Aranda Aguilar, Enrique
Institut Català de la Salut
[Vivancos A] Grup de genòmica del Càncer, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Aranda E, Gómez-España MA] Department of Medical Oncology, Reina Sofía University Hospital, CIBERONC, Córdoba, Spain. [Benavides M] Department of Medical Oncology, Hospital Universitario Regional y Virgen de la Victoria, Málaga, Spain. [Élez E] Servei d’Oncologia Mèdica, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. [Toledano M] IMIBIC Instituto Maimonides Investigación Biomédica de Córdoba, Córdoba, Spain.
Hospital Verge de la Cinta de Tortosa
2019-08-21T06:01:24Z
2019-08-21T06:01:24Z
2019-06-20
Biopsy; KRAS mutation; Colorectal cancer
Biòpsia; Mutació KRAS, Càncer colorectal
Biopsia; Mutación KRAS, Cáncer colorrectal
KRAS mutations are common in colorectal cancer (CRC). In this setting, mutation status determination in circulating-free DNA from blood samples (liquid biopsy) has been shown to be a viable alternative to tissue testing. The objective of this study was to compare the sensitivity of two liquid biopsy methods for detecting KRAS mutations in plasma samples from metastatic CRC patients. Samples with a positive (KRAS-MUT+) result and a mutant allelic fraction (MAF) < 5% according to the OncoBEAM RAS CRC assay were pairly analyzed by the Idylla ctKRAS Mutation Test (n = 116). In a cohort of 71 patients with at least 1 year of follow-up, the progression-free survival (PFS) was determined according to MAF values. Idylla detected KRAS mutations in 81/116 OncoBEAM KRAS-MUT+ samples with MAF < 5% and in 48/79 samples with MAF < 1%. Concordance between OncoBEAM and Idylla significantly improved at higher MAF values. PFS rates at 6 and 12 months tended to be lower in patients with MAF levels between 1% and 5% than in those with levels <1%. OncoBEAM demonstrated greater sensitivity for plasma detection of KRAS mutations than Idylla. Importantly, our data identified a "gray zone" below 1% MAF where Idylla showed reduced KRAS mutation detection, highlighting the importance of an accurate method to provide the mutational status of CRC patients.
English
Còlon - Càncer - Diagnòstic; Oncogens Ras; Biòpsia; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; Other subheadings::Other subheadings::/diagnosis; CHEMICALS AND DRUGS::Enzymes and Coenzymes::Enzymes::Hydrolases::Acid Anhydride Hydrolases::GTP Phosphohydrolases::GTP-Binding Proteins::Monomeric GTP-Binding Proteins::ras Proteins::Proto-Oncogene Proteins p21(ras); Other subheadings::Other subheadings::Other subheadings::/genetics; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cytodiagnosis::Biopsy::Liquid Biopsy; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales; Otros calificadores::Otros calificadores::/diagnóstico; COMPUESTOS QUÍMICOS Y DROGAS::enzimas y coenzimas::enzimas::hidrolasas::ácido anhídrido hidrolasas::GTP fosfohidrolasas::proteínas de unión al GTP::proteínas de unión al GTP monoméricas::proteínas ras::proteínas protooncogénicas p21(ras); Otros calificadores::Otros calificadores::Otros calificadores::/genética; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico::técnicas citológicas::citodiagnóstico::biopsia::biopsia líquida
Nature Research
Scientific Reports;9(1)
https://www.nature.com/articles/s41598-019-45616-y
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
